Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > News Claritas and Salzman to create

<< Previous

Bullboard Posts

Next >>

Post by WORKINMONTANAon Mar 05, 2021 8:08am

165 Views

Post# 32725998

News Claritas and Salzman to create

From the Kalyteran.co webpage.

[url=https://kalyteran.co/index.php?/topic/662-news-claritas-and-salzman-to-create-nitric-oxide-releasing-compound-for-covid-19/]https://kalyteran.co/index.php?/topic/662-news-claritas-and-salzman-to-create-nitric-oxide-releasing-compound-for-covid-19/[/url]

https://www.pharmaceutical-technology.com/news/claritas-salzman-nitric-oxide/

https://clarita.ca/index.php/articles/2-uncategorised/28-is-r-107-the-answer-to-the-covid-crisis

Claritas Therapeutics, a cutting edge R & D company with laboratories in Israel and Massachusetts is currently working on a combined treatment/anti viral application that can not only treat the damage COVID 19 has done to the lungs and organs but, also inhibit the replication of the genome responsible for infecting the human host.

Their Nitric Oxide prodrug, Radikal 107 https://kalyteran.co/kalytera/index.php/kalytera-and-r-107 has been enormously successful in large animal testing and, is about to enter Phase one human trials early in the New Year. The FDA has designated R-107 for Fast Track and the company will be applying for breakthrough therapy designation soon.

Robert Farrell, the CEO of Claritas Therapeutics has called R-107 a potential "game changer in the field of medical treatment for both Sars Cov Viruses and lung injuries" and has stated "Problems associated with making successful vaccines, and in particular, vaccines for Corona Viruses are varied and serious and will probably dog any potential global vaccine candidate far into the future. Having a treatment such as ours to work alongside them, just for the COVID application, is an extremely valuable tool."